Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression

@article{Jain2010EnhancementOC,
  title={Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression},
  author={Dilip Jain and Nila Patel and Melanie Shelton and Alakananda Basu and Rouel S. Roque and Wolfram Siede},
  journal={Cancer Chemotherapy and Pharmacology},
  year={2010},
  volume={66},
  pages={945-952}
}
PurposeNSC109268 has been described previously as inhibitor of proteasomal degradation and of phosphatase 2Cα. In a yeast screen, we isolated NSC109268 as an agent altering sensitivity to DNA-damaging agents. We found that NSC109268 and the related compound NSC109272 enhance cellular sensitivity to cis- and transplatin but reduce sensitivity to nitrogen mustard. We explored if similar effects could be found in human cancer cells and if cell cycle analysis could hint at the underlying molecular… 

Figures from this paper

NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner
TLDR
It is demonstrated that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin independent of p53, which is believed to be a critical role in DNA damage-induced apoptosis.
articleNSC 109268 potentiates cisplatin-induced cell death in a p 53-independent manner
TLDR
It is demonstrated that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin, which is believed to kill cancer cells by inducing apoptosis and a defect in apoptotic signaling can contribute to drug resistance.
Rad5 Template Switch Pathway of DNA Damage Tolerance Determines Synergism between Cisplatin and NSC109268 in Saccharomyces cerevisiae
TLDR
In the CP hypersensitive ptc2Δptc3Δpph3ά yeast strain, cellular sensitization to CP by NSC109268 was greatly reduced, and it is suggested that NSC 109268 affects CP sensitivity by inhibiting the activity of unknown protein(s) whose dephosphorylation is required for the template switch pathway.
Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment
TLDR
Nilotinib may be a feasible targeted therapy option for the treatment of ovarian cancer after testing its preclinical activity in ovarian cancer cell lines with different tyrosine kinase expression patterns.
Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways
TLDR
The target complex inhibited the proliferation of Caov-3 and HT-29 cells, resulting in the arrest of the cell cycle and induction of apoptosis via the stimulation of the p53 and caspase-8 pathways.
P2Y11 impairs cell proliferation by induction of cell cycle arrest and sensitizes endothelial cells to cisplatin‐induced cell death
TLDR
It is suggested that extracellular ATP impairs cell proliferation by triggering signaling to induce cell cycle arrest and sensitizes cell to death via P2Y11 in endothelial cells.
SKY1 and IXR1 interactions, their effects on cisplatin and spermine resistance in Saccharomyces cerevisiae.
TLDR
It is found that the effects of these deletions are highly dependent on the genetic background of the selected strains, valuable in the selection of yeast strains to be used in genetic screenings of compounds with putative pharmacological interest.
Binding and Anticancer Properties of Plumbagin with Human Serum Albumin
TLDR
It is demonstrated that plumbagin interacts with human serum albumin, although its binding affinity may be affected to various extents by different compounds, and this study contributes to the rational design and development of plumberagin‐based drugs and a drug–human serumalbumin delivery system.
Checkpoint Control of DNA Repair in Yeast
TLDR
This review summarizes current information known about the checkpoint response to agents that elicit both the G2/M checkpoint and the intra-S phase checkpoint and how cells adapt to unrepaired DNA damage.
...
1
2
...

References

SHOWING 1-10 OF 33 REFERENCES
Cisplatin Rapidly Down-regulates Its Own Influx Transporter hCTR1 in Cultured Human Ovarian Carcinoma Cells
TLDR
DDP down-regulated the amount of its major influx transporter in cultured human ovarian carcinoma cells in a concentration- and time-dependent manner and it occurred very quickly relative to the half-life of the drug.
Influence of cisplatin on cell-cycle progression in xenografted human head and neck carcinomas
TLDR
The hindrance of cell traversal through the S phase obviously represents the main and significant cytokinetic event, which indicates a potent antitumor effect for cisplatin that leads to pronounced tumor regression, and supports the hypothesis that inhibition of DNA synthesis is the mechanism underlying the cytotoxicity of cisPlatin.
Proteasome inhibitors remarkably prevent translesion replication in cancer cells but not normal cells
TLDR
Translesion replication would be an effective target of proteasome inhibitors for cancer chemotherapy by which cancer cells can be efficiently sensitized to DNA‐damaging antineoplastic agents, such as cisplatin.
Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
TLDR
Results indicate that the bypass response in the C13* line has some degree of specificity for cisplatin adducts, and the specificity of bypass in these cell lines coincided well with the Specificity of resistance to each agent.
Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin
TLDR
It is shown that HGF and CDDP modulate transcription in ovarian cancer cells and that this transcriptional response is involved in apoptosis regulation.
Mechanisms of resistance to cisplatin and carboplatin.
  • D. Stewart
  • Biology
    Critical reviews in oncology/hematology
  • 2007
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
TLDR
It is demonstrated that deletion of the yeast CTR1 gene, which encodes a high-affinity copper transporter, results in increased cis platin resistance and reduced intracellular accumulation of cisplatin, and proposed that cisplin uptake is mediated by the copper transporter Ctr1p in yeast and mammals.
Enhanced Delivery of Cisplatin to Intraperitoneal Ovarian Carcinomas Mediated by the Effects of Bortezomib on the Human Copper Transporter 1
TLDR
Proteasomal inhibition prevented cisplatin-induced down-regulation of hCTR1 in ovarian cancer cells and enhanced drug uptake and cell killing in a synergistic manner.
Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis
TLDR
A group of Wip1 inhibitors with anticancer properties both in vitro and in vivo is reported, and it is proposed that these agents may serve as lead compounds for the development of anticancer drugs targeting Wip 1 phosphatase.
...
1
2
3
4
...